FDA Puts Brakes on Fast-Track Drug Reviews Amid Safety Concerns

The FDA has delayed reviews of two drugs in the Trump administration's fast-track program due to safety concerns, including a patient's death. The agency's reassessment raises questions about the program's effectiveness and the potential politicization of drug approvals.

The U.S. Food and Drug Administration (FDA) has postponed the review of two drugs under the Trump administration's rapid approval initiative. Internal documents noted concerns over safety and effectiveness, particularly highlighting a patient's death linked to one of the treatments.

The FDA extended the review of Disc Medicine's drug for a rare blood disorder and Sanofi's Tzield for type 1 diabetes, citing trial data issues and adverse events. This move raises questions about the program's ability to rigorously evaluate critical medications intended for fast-track approval.

Experts suggest the delay reflects the FDA's commitment to thorough evaluation despite political pressures, although concerns remain about the influence of the Trump administration's selection process and the program's potential to prioritize politically advantageous drugs.

(With inputs from agencies.)